TKT and central nervous system cancer: In 1996, Eck et al. published the first phase I clinical trial, where the pro-drug activating enzyme Herpes simplex virus—thymidine kinase (HSV-tk) packed into an adenovirus was used with the intention to treat patients with recurrent gliomas [38].